Tandem Diabetes CareTNDM
Market Cap: $2.78B
About: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Employees: 2,400
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
784% more call options, than puts
Call options by funds: $135M | Put options by funds: $15.3M
70% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 37
38% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 90
11% more capital invested
Capital invested by funds: $2.67B [Q1] → $2.96B (+$292M) [Q2]
9% more funds holding
Funds holding: 288 [Q1] → 314 (+26) [Q2]
1.06% less ownership
Funds ownership: 114.99% [Q1] → 113.93% (-1.06%) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 2 (-2) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Morgan Stanley Patrick Wood 69% 1-year accuracy 9 / 13 met price target | 6%upside $45 | Equal-Weight Initiated | 22 Aug 2024 |
Canaccord Genuity William Plovanic 50% 1-year accuracy 14 / 28 met price target | 34%upside $57 | Buy Initiated | 8 Aug 2024 |
Barclays Matt Miksic 59% 1-year accuracy 17 / 29 met price target | 37%upside $58 | Overweight Maintained | 5 Aug 2024 |
Baird Jeff Johnson 58% 1-year accuracy 7 / 12 met price target | 8%downside $39 | Neutral Maintained | 2 Aug 2024 |
Piper Sandler Matt O'Brien 50% 1-year accuracy 22 / 44 met price target | 30%upside $55 | Overweight Reiterated | 2 Aug 2024 |
Financial journalist opinion
Based on 6 articles about TNDM published over the past 30 days